CRISPR Therapeutics AG officer Raju Prasad filed a Form 144 notice of proposed sale of 79,393 common shares on November 6, 2026, with an aggregate market value of $3,960,183.20, to be executed through Morgan Stanley Smith Barney LLC.
Key Highlights
- Proposed seller: Raju Prasad, identified as an officer of CRISPR Therapeutics AG, filed the notice on November 6, 2026.
- Shares proposed for sale: 79,393 common shares with an aggregate market value of $3,960,183.20, according to the filing.
- Shares outstanding: The filing reports 97,000,813 common shares outstanding.
- Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
- Acquisition sources: Securities to be sold were acquired through a stock option exercise on November 6, 2026, and multiple restricted stock grants from the issuer between March 2025 and March 2026.
- No sales in past 3 months: The filing states nothing to report under securities sold during the past three months.
- Exchange listed: NASDAQ, under issuer CRISPR Therapeutics AG (NASDAQ:CRSP is not stated in the filing; the filing identifies the exchange as NASDAQ).
CRISPR Therapeutics Officer Prasad Proposes Sale of Common Shares Acquired via Option Exercise and Restricted Stock
According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Raju Prasad, an officer of CRISPR Therapeutics AG, proposed to sell 79,393 shares of the company's common stock. The approximate date of sale listed in the filing is November 6, 2026, with the transaction to be facilitated through Morgan Stanley Smith Barney LLC Executive Financial Services in New York. The aggregate market value of the shares proposed for sale is stated as $3,960,183.20, and total shares outstanding are reported as 97,000,813.
The filing details multiple acquisition transactions underlying the proposed sale. The largest single block, 64,578 shares, was acquired on November 6, 2026, through a stock option exercise from the issuer, with payment made in cash. The remaining shares were acquired as restricted stock from the issuer across several dates: 1,447 shares on March 10, 2025; 517 shares on March 14, 2025; 1,565 shares on March 17, 2025; 2,488 shares on March 20, 2025; 4,021 shares on March 10, 2026; 1,827 shares on March 12, 2026; 1,158 shares on March 14, 2026; and 1,792 shares on March 20, 2026.
The filing reports no securities of the issuer were sold by Prasad during the past three months. The notice was signed by Raju Yashaswi Prasad and dated November 6, 2026. CRISPR Therapeutics AG is headquartered at Baarerstrasse 14, Zug, Switzerland, and its securities trade on NASDAQ. The SEC file number for the issuer is listed as 001-37923.
What Was Disclosed
CRISPR Therapeutics AG officer Raju Prasad filed a Form 144 on November 6, 2026, proposing to sell 79,393 common shares valued at $3,960,183.20. Shares were acquired through a stock option exercise and multiple restricted stock grants from the issuer between March 2025 and March 2026.




Please wait processing your request...